Uncategorized
Travecta Therapeutics Appoints Douglas C. Hicks as Chief Business Officer
PHILADELPHIA--(BUSINESS WIRE)--Travecta Therapeutics, an emerging biotech company developing a platform that leverages its proprietary knowledge of the MFSD2a Transport for the targeted delivery of therapeutic agents across the blood-brain barrier, announces it has appointed Douglas C. Hicks as Chief Business Officer. Mr. Hicks will serve on the Travecta Therapeutics executive leadership team and lead business development and corporate strategy for the company. “Doug joins our team at a critica